Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy.

Therapeutic outcomes in solid tumors are shaped by drug potency and by heterogeneous tumor microenvironments that restrict vascular access, stromal penetration, local release, immune activation and durable response. Multifunctional nanotherapeutics have been developed to engage these barriers through pharmacokinetic optimization, vascular and stromal modulation, endogenous and exogenous stimuli-responsive release, immune-oriented intervention and imaging-guided treatment. However, the field remains challenged by heterogeneous human enhanced permeability and retention effects, uncertain translation of active targeting, context-dependent stromal biology, incomplete immune readouts and increasing chemistry-manufacturing-controls complexity as additional modules are integrated. This review organizes nanoplatforms through a tumor microenvironment phenotype-informed design logic that links biological barriers to design objectives, module choices, measurable readouts, evidence strength and translational constraints. Within this framework, we critically examine representative nanotherapeutic strategies across pharmacokinetic and biodistribution-oriented design, vascular and stromal normalization, tumor microenvironment-responsive activation, immune priming and intratumoral reprogramming, and clinically relevant theranostic approaches. We further discuss route of administration, patient stratification, safety, value assessment and rational platform simplification, emphasizing that future progress is more likely to depend on phenotype-matched and evidence-stratified deployment than on indiscriminate functional stacking.